Moderna CEO Stephane Bancel on INT trial results: There's duration of efficacy which is exciting

Stephane Bancel, Moderna CEO, joins 'The Exchange' to discuss the company's INT results, how big a drug it could become and ...

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...

Moderna (MRNA) Is Down 5.5% After FDA Sets Flu Vaccine Review, Tightens Lawsuit Venue Rules - What's Changed

On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US ...

Moderna's mRNA flu vaccine is more effective than the standard shot in a late-stage trial

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.

AFP / Moderna shares are surging after a report the drugmaker confirmed it's working on a potential hantavirus vaccine. Several people have tested positive for the rare hantavirus on the cruise ship ...

Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales

By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, helped by better-than-expected sales of its ...

Hantavirus stirs vaccine skeptics, Moderna questions, prediction conspiracy

Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.